Drug · Small Molecule

Pazopanib

CI-DRUG-00000460Explore in graph →NCIt C74547 CHEMBL477772 CIViC Approved

Regulatory

Approvals (12)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	—	Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes.	approved	Jun 14, 2010

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 14 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	17	9	16	203	12	CA, EU, US	Oct 19, 2009	2002-12
Malignant Kidney Neoplasm	Approved	Phase 4	5	2	8	54	1	US	Oct 19, 2009	Sep 28, 2004
Malignant Breast Neoplasm	Phase4	Phase 4	0	0	0	10	0	—	—	2007-01
Malignant Ovarian Neoplasm	Phase4	Phase 4	0	0	1	14	0

Curated evidence

Clinical evidence (27)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–27 of 27 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT4 Amplification2
Pazopanib	Angiosarcoma

Clinical trials

Trials with this intervention (208)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 208 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01552356	Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors	active not recruiting	Phase 1	54	National Cancer Institute (NCI)NIH	1	Sep 9, 2026	clinicaltrials
NCT01841736	Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors	active not recruiting	Phase 2

Molecule

Record

Kind: Small Molecule
Mechanism: Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Tyrosine-protein kinase ITK/TSK inhibitor
Targets: 11 genes
UNII: 33Y9ANM545
Aliases: AURO-PAZOPANIB, Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, GW-786034, GW786034, NSC-752782, Pazopanib, Pazopanib Hydrochloride, PMS-PAZOPANIB, SANDOZ PAZOPANIB, VOTRIENT

Data updated 17 hours agoSource updated unknown

Identifiers

Codes (13)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01EX03	PAZOPANIB
ATC (WHO)	L01XE11

FGFR3 Amplification2
Pazopanib	Ewing Sarcoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID7835 Clinical trial of soft tissue sarcoma patients found no responses to pazopanib + trametinib combination in Ewing sarcoma patients. Comparison was done to previously treated Ewing sarcoma that responde… (full text at CIViC) PMID 28377484 · Subbiah et al., 2017 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID7955 Patients with breast cancer had their tumor samples analyzed by Foundation Medicine in order to determine an appropriate clinical trial with targeted therapy or retrospectively to correlate with respo… (full text at CIViC) PMID 27489863 · Wheler et al., 2016 · Open in CIViC	civic

FGFR3 S249C2
Pazopanib	Transitional Cell Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1603 Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlar… (full text at CIViC) PMID 25766722 · Palma et al., 2015 · Open in CIViC	civic
〃	Transitional Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7834 Case study of a 74 year-old female with pulmonary metastases of urothelial carcinoma. Patient did not respond to carboplatin/gemcitabine or other second- and third-line therapies including MELK inhib… (full text at CIViC) PMID 27271022 · Sethakorn et al., 2016 · Open in CIViC	civic